Current Hematologic Malignancy Reports

Journal Title：Current Hematologic Malignancy Reports

his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy.

We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.

本期刊旨在提供国际专家的清晰、有见地、平衡的贡献，回顾与血液系统恶性肿瘤的诊断、治疗、管理和预防相关的最重要的、最近发表的临床发现。

我们通过任命国际权威人士担任关键主题领域的分部编辑来实现这一目标，例如白血病、淋巴瘤、骨髓瘤、T 细胞和其他淋巴增生性恶性肿瘤。分部编辑依次选择主题，由顶尖专家撰写全面的评论文章，强调新发展和最近发表的重要论文，并通过带注释的参考文献列表突出显示。国际编辑委员会审查年度目录，推荐对其国家/地区特别感兴趣的文章，并确保主题是最新的并包括新兴研究。还提供该领域知名人物的评论。

Current Hematologic Malignancy Reports创刊于2006年，由Springer US出版商出版，收稿方向涵盖ONCOLOGY - HEMATOLOGY全领域，此刊是中等级别的SCI期刊，所以过审相对来讲不是特别难，但是该刊专业认可度不错，仍然是一本值得选择的SCI期刊 。平均审稿速度 12周，或约稿 ，影响因子指数2.7，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。